Form 4: Artiva Biotherapeutics COO Sells Shares for Tax

Artiva Biotherapeutics' COO, CLO, Secretary, and Compliance Officer, Jennifer Bush, disposed of 3,055 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Jennifer Bush, the Chief Operating Officer, Chief Legal Officer, Secretary, and Compliance Officer of Artiva Biotherapeutics, Inc. (ARTV), reported a transaction.
• On November 15, 2025, Ms. Bush disposed of 3,055 shares of common stock.
• The disposition was made at a price of $3.25 per share.
• This transaction represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
• Following this transaction, Ms. Bush beneficially owns 148,048 shares of common stock directly.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The sentiment is neutral as this Form 4 reports a routine, non-discretionary disposition of shares to cover tax obligations upon the vesting of restricted stock units, which is a common occurrence for executives.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is a routine insider transaction related to compensation and tax obligations, and it does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary transaction for tax purposes and does not reflect a change in management's confidence or company fundamentals.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary disposition of shares by an insider to cover tax obligations upon the vesting of restricted stock units. It does not indicate a change in the insider's investment conviction or the company's fundamentals, thus a 'hold' recommendation is maintained as there is no new information to alter an existing investment thesis.

Keywords

Artiva Biotherapeutics, ARTV, Form 4, Insider Transaction, Stock Disposition, Tax Withholding, Restricted Stock Units, Jennifer Bush, Rule 10b5-1(c)